-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 15, 2021, the US FDA announced the approval of Orencia (abatacept)'s supplementary biological product license application (sBLA) for use in combination with certain immunosuppressive agents to prevent acute graft-versus-host in children or adult patients over 2 years old Disease (aGVHD)
HSCT is an effective method for the treatment of aggressive leukemia and other hematological malignancies, and is usually the only option for cure
GVHD occurs when donor T cells recognize the patient's healthy cells as foreign objects and start to attack
This approval is based on the results of a Phase 2 clinical trial and a study based on real-world data
Note: The original text has been deleted
Reference materials:
[1] FDA Approves First Drug to Prevent Graft Versus Host Disease.